


## Absolute Configuration of Scyphostatin

Shoichi Saito, Natsuki Tanaka, Katsumi Fujimoto, and Hiroshi Kogen\*

*Exploratory Chemistry Research Laboratories, Sankyo Co., Ltd., Hiromachi 1-chome,  
2-58, Shinagawa-ku, Tokyo 140-8710, Japan**hkogen@shina.sankyo.co.jp*

Received December 14, 1999

## ABSTRACT



The absolute configuration of the side chain of scyphostatin (**1**) has been established. The chemical degradation of **1** gave **4** and **9**, which correspond to the C7'–C12' and C13'–C16' fragments of the natural products, respectively. The spectroscopic data and  $[\alpha]_D$  values of both compounds were compared to those of authentic samples. The results show that the absolute configuration of **1** is 8'R,10'S,14'R.

Scyphostatin (**1**) was isolated as a potent inhibitor of neutral sphingomyelinase by Ogita et al. in 1997.<sup>1</sup> This compound is the first low-molecular-weight inhibitor of the enzyme, either from natural sources or of synthetic origin. These factors combine with interesting biological activity and unique structure to make **1** a synthetic target of enormous interest (Figure 1).




Figure 1.

A previous structure elucidation of **1** only determined the absolute stereochemistry of the epoxy cyclohexenone moiety.<sup>1a</sup>

The stereochemistry of the side chain, containing three asymmetric centers, still remains unelucidated. In this communication, we describe the entire stereochemical structure of **1**, including the absolute stereochemistry, by degradation of the side chain followed by correlation to known chiral compounds.

Natural scyphostatin (**1**) was treated with potassium hydroxide in methanol under reflux conditions, and subsequent reaction with (trimethylsilyl)diazomethane gave methyl ester **2** ( $[\alpha]_D = -2.5$  (c 0.50, CHCl<sub>3</sub>)) in 61% yield (two steps). Oxidative cleavage of the ester **2** was accomplished by ozonolysis followed by reductive workup to yield diol **3**, corresponding to the C7'–C12' fragment. It contains both the C8' and C10' asymmetric centers as a mixture of inseparable diastereoisomers. Treatment of the diol **3** with benzoyl chloride and triethylamine followed by the Dess–Martin reagent<sup>2</sup> provided keto ester **4** ( $[\alpha]_D = -7.0$  (c 0.53, CHCl<sub>3</sub>)) in 80% yield (two steps) as a single isomer. To determine the absolute stereochemistry of **4**, the optically active carboxylic acid **6**, a chiral starting material which has a known absolute configuration,<sup>3</sup> was readily derived from lactone (±)-**5**.<sup>3,4</sup> Reduction of **6** ( $[\alpha]_D = -5.7$  (c 4.60,


(1) (a) Tanaka, M.; Nara, F.; Suzuki-Konagai, K.; Hosoya, T.; Ogita, T. *J. Am. Chem. Soc.* **1997**, *119*, 7871. (b) Nara, F.; Tanaka, M.; Hosoya, T.; Suzuki-Konagai, K.; Ogita, T. *J. Antibiot.* **1999**, *52*, 525. (c) Nara, F.; Tanaka, M.; Masuda-Inoue, S.; Yamamoto, Y.; Doi-Yoshioka, H.; Suzuki-Konagai, K.; Kumakura, S.; Ogita, T. *J. Antibiot.* **1999**, *52*, 531.

(2) Dess, D. B.; Martin, J. C. *J. Org. Chem.* **1983**, *48*, 4155.

(3) Mori, K.; Kuwahara, S. *Tetrahedron* **1986**, *42*, 5539.

(4) (a) Ungnade, H. E.; Nightingale, D. V. *J. Am. Chem. Soc.* **1944**, *66*, 1218. (b) Mori, K.; Kuwahara, S. *Tetrahedron* **1986**, *42*, 5545.

### Scheme 1



(a) KOH, MeOH, reflux; (b) Me<sub>3</sub>SiCHN<sub>2</sub>, MeOH, benzene, rt; (c) O<sub>3</sub>, MeOH, -40 to -10 °C; (d) PhCOCl, cat. DMAP, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, rt; (e) Dess–Martin reagent, CH<sub>2</sub>Cl<sub>2</sub>, rt; (f) BH<sub>3</sub>–Me<sub>2</sub>S, THF, 0 °C.

CHCl<sub>3</sub>), lit.<sup>3</sup>  $[\alpha]_D = -4.2$  (c 8.69, CHCl<sub>3</sub>)) with borane–methyl sulfide complex followed by treatment with benzoyl chloride and triethylamine provided the monobenzoyl ester **7** in 47% yield (two steps). Dess–Martin oxidation of the secondary hydroxyl group of **7** afforded the keto ester **8** ( $[\alpha]_D = -7.0$  (c 2.35, CHCl<sub>3</sub>)) in 71% yield (Scheme 1). Its spectral data and physical properties (<sup>1</sup>H and <sup>13</sup>C, IR, and  $[\alpha]_D$ ) were identical with those of the degradation product **4**. This result shows that the absolute configuration of **4** is 8'*R*,10'*S*. During these operations the compound corresponding to the C13'–C16' moiety could not be isolated.

To determine the stereochemistry of chiral center C14', we attempted the isolation of the C13'–C16' fragment as its 2-methylbutyric acid derivative (Scheme 2). The ester **2**

mp 52.5–53.5 °C) in 64% yield (two steps).<sup>7</sup> An authentic sample was prepared from commercially available (*S*)-(+)-2-methylbutyric acid (**10**)<sup>8</sup> under the same esterification conditions in 98% yield. The physical and spectroscopic data of the authentic *p*-bromophenacyl ester (+)-**9** ( $[\alpha]_D = +12.1$  (c 0.60, CHCl<sub>3</sub>); mp 53–54 °C) were identical with those of the degradation product (–)-**9** (<sup>1</sup>H NMR, <sup>13</sup>C NMR, IR, and HRMS), with the exception of the sign of the optical rotation ( $[\alpha]_D = -12.6$ ). This result means that the absolute configuration of C14' is *R*. These results in total offered the complete stereochemical structure of scyphostatin (**1**) as 8'*R*,10'*S*,14'*R*, as shown in Figure 1.

**Acknowledgment.** We thank Drs. Takeshi Ogita and Masahiro Tanaka in our laboratories for providing us with natural scyphostatin.


**Supporting Information Available:** Spectral data for compounds **2**, **4**, **8**, **9**, and **11** and representative <sup>1</sup>H and <sup>13</sup>C NMR spectra. This material is available free of charge via the Internet at <http://pubs.acs.org>.

OL991351P

(5) Carlsen, P. H. J.; Katsuki, T.; Martin, V. S.; Sharpless, L. B. *J. Org. Chem.* **1981**, 46, 3938.


(6) Clark, J. H.; Miller, J. M. *Tetrahedron Lett.* **1977**, 599.

(7) Another *p*-bromophenacyl ester, **11**, was also obtained in 70% yield without epimerization. The compound was identical with an authentic sample, which was derived from **6** in two steps ((a) *p*-bromophenacyl bromide, KF, DMF (90%); (b) Dess–Martin oxidation (93%)).



(8) (*S*)-(+)-2-Methylbutyric acid was purchased from Aldrich Chemical Co.

### Scheme 2



(a) RuCl<sub>3</sub>, NaIO<sub>4</sub>, MeCN–CCl<sub>4</sub>–H<sub>2</sub>O (2 : 2 : 3), rt; (b) KF, *p*-bromophenacyl bromide, DMF, rt.

was treated with RuCl<sub>3</sub>/NaIO<sub>4</sub><sup>5</sup> and esterified with *p*-bromophenacyl bromide and KF in DMF,<sup>6</sup> furnishing the *p*-bromophenacyl ester (–)-**9** ( $[\alpha]_D = -12.6$  (c 0.64, CHCl<sub>3</sub>);